Attached files
| file | filename |
|---|---|
| EX-99.1 - WINDTREE THERAPEUTICS INC /DE/ | v197152_ex99-1.htm |
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
___________________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
September
15, 2010
Date of
Report (Date of earliest event reported)
Discovery
Laboratories, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-26422
|
94-3171943
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
Number)
|
2600
Kelly Road, Suite 100
Warrington,
Pennsylvania 18976
(Address
of principal executive offices)
(215)
488-9300
(Registrant's
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
1.02.
|
Termination of a
Material Definitive
Agreement.
|
On
September 15, 2010, Charles F. Katzer submitted his resignation as Senior Vice
President and Chief Technology Officer of Discovery Laboratories, Inc. (the
“Company”) effective September 24, 2010. As a result, Mr. Katzer’s
employment agreement with the Company will terminate on that
date. The agreement was filed with the SEC on March 10, 2010 as
Exhibits 10.24 – 10.26 to the Company’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2009.
On
September 21, 2010, the Company issued a press release announcing the
resignation of Mr. Katzer and the hiring of Thomas C. Hoy, who will serve as
Vice President, Manufacturing Operations. Mr. Hoy has significant
experience in product manufacturing, including over 20 years at Johnson &
Johnson. He will join the Company effective September 30,
2010. The press release is attached as Exhibit 99.1.
|
Item
9.01.
|
Financial Statements
and Exhibits.
|
|
|
(d)
|
Exhibits
|
|
|
99.1
|
Press
Release dated September 21, 2010.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Discovery
Laboratories, Inc.
|
|||
|
|
By:
|
/s/ W. Thomas Amick | |
| Name: W. Thomas Amick | |||
|
Title: Chairman
of the Board and Interim
|
|||
|
Chief
Executive Officer
|
|||
Date: September
21, 2010
3